These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 17400869)

  • 1. U.S. Food and drug administration analysis of strokes associated with raloxifene.
    Wyeth J; Green L; Avigan M
    Obstet Gynecol; 2007 Apr; 109(4):999. PubMed ID: 17400869
    [No Abstract]   [Full Text] [Related]  

  • 2. Raloxifene prevails in STAR trial, may face easier road to acceptance than previous drugs.
    Vastag B
    J Natl Cancer Inst; 2006 Jun; 98(11):733-5. PubMed ID: 16757696
    [No Abstract]   [Full Text] [Related]  

  • 3. Osteoporosis treatment: raloxifene (Evista) and stroke mortality.
    Wooltorton E
    CMAJ; 2006 Jul; 175(2):147. PubMed ID: 16804122
    [No Abstract]   [Full Text] [Related]  

  • 4. Lessons from RUTH.
    Pines A
    Climacteric; 2006 Oct; 9(5):323-4. PubMed ID: 17000580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis.
    Adomaityte J; Farooq M; Qayyum R
    Thromb Haemost; 2008 Feb; 99(2):338-42. PubMed ID: 18278183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raloxifene: handle with care.
    Pritchard KI; Levine M; Walley B;
    CMAJ; 2001 Jul; 165(2):151, 153. PubMed ID: 11501451
    [No Abstract]   [Full Text] [Related]  

  • 7. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.
    Eilertsen AL; Liestøl S; Mowinckel MC; Hemker HC; Sandset PM
    Thromb Haemost; 2007 Jun; 97(6):938-43. PubMed ID: 17549295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive pigmentary purpura related to raloxifene.
    Erbagci Z; Tuncel A; Erkilic S; Ozkur M
    Saudi Med J; 2005 Feb; 26(2):314-6. PubMed ID: 15770314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regression of hepatic adenomata after cessation of selective oestrogen receptor modulator.
    Carswell KA; Belgaumkar A; Karani J; Patel AG
    Liver Int; 2009 Jan; 29(1):73. PubMed ID: 18681924
    [No Abstract]   [Full Text] [Related]  

  • 10. Tamoxifen: to use or not to use.
    Yin CS
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):129-30. PubMed ID: 18400603
    [No Abstract]   [Full Text] [Related]  

  • 11. Raloxifene and risk for stroke based on the framingham stroke risk score.
    Barrett-Connor E; Cox DA; Song J; Mitlak B; Mosca L; Grady D
    Am J Med; 2009 Aug; 122(8):754-61. PubMed ID: 19540454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB
    J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter by Choi et al regarding article, "Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the raloxifene use for the heart trial: results of subgroup analyses by age and other factors".
    Choi BG; Vilahur G; Badimon JJ
    Circulation; 2009 Oct; 120(17):e147; author reply e148. PubMed ID: 19858421
    [No Abstract]   [Full Text] [Related]  

  • 16. [Relation between hormonal therapy and tibolone with SERMs in postmenopausal women's myomes growth].
    Carranza Lira S
    Ginecol Obstet Mex; 2008 Oct; 76(10):610-4. PubMed ID: 19062511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenylpropanolamine and hemorrhagic stroke in the Hemorrhagic Stroke Project: a reappraisal in the context of science, the Food and Drug Administration, and the law.
    Stier BG; Hennekens CH
    Ann Epidemiol; 2006 Jan; 16(1):49-52. PubMed ID: 16216529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive effects of short-term use of raloxifene: a randomized clinical trial.
    Buckwalter JG; Geiger AM; Parsons TD; Handler J; Howes J; Lehmer RR
    Int J Neurosci; 2007 Nov; 117(11):1579-90. PubMed ID: 17917927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute stroke therapy with tissue plasminogen activator (tPA) since it was approved by the U.S. Food and Drug Administration (FDA).
    Zivin JA
    Ann Neurol; 2009 Jul; 66(1):6-10. PubMed ID: 19681102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.